Calder Development Associates

Calder Biosciences, operating legally as Calder Development Associates, is a biotechnology company dedicated to the development of highly stable and immunogenic subunit vaccines for respiratory viruses. The company utilizes a proprietary d-tyrosine (DT) cross-linking platform, a form of "molecular stapling" that stabilizes viral antigens in their most potent, pre-fusion conformations. Their lead program is a Respiratory Syncytial Virus (RSV) vaccine candidate designed to provide superior immunogenicity and stability compared to traditional vaccine methods. Beyond RSV, Calder is applying its stabilization technology to develop universal influenza vaccines and candidates for other high-impact viral pathogens. Headquartered in Brooklyn, New York, the company has received significant support through federal research grants and maintains collaborations with leading academic institutions.